The Computational Pathology Market is growing rapidly, with a projected value of USD 1251.72 million by 2032 and a CAGR of 8.62%. The U.S. market alone is expected to reach USD 372.18 million by 2032. Advanced technologies like AI and machine learning are enhancing diagnostic precision and transforming healthcare systems globally.

The increasing prevalence of chronic diseases and the shift towards precision medicine are driving the adoption of computational tools. AI-enabled platforms are automating complex tasks like tumor detection and tissue pattern recognition. As demand for data-driven diagnostic solutions rises, computational pathology is becoming a crucial component of modern healthcare.

In 2024, the software segment dominated the computational pathology market with a 68.2% share, while services are expected to grow rapidly in the coming years. Disease diagnosis accounted for 46.15% of the market share in 2024, with academic research projected to have the fastest growth. Machine learning was the leading technology segment in 2024, with Natural Language Processing Models expected to grow rapidly.

Hospitals and diagnostic labs held 68.14% of the computational pathology market share in 2024, with biotechnology and pharmaceutical companies showing the highest growth potential. North America led the market in 2024, with Asia Pacific expected to be the fastest-growing region due to increasing healthcare spending and the rising burden of chronic diseases.

Key companies profiled in the market include Koninklijke Philips, Roche, PathAI, and Olympus. Recent developments include Roche’s Breakthrough Device Designation for its VENTANA TROP2 RxDx Device and PathAI’s collaboration with Northwestern Medicine. The market is projected to continue growing as computational pathology plays a vital role in precision diagnostics and drug development.

Read more at GlobeNewswire: Computational Pathology Market Projected to Reach USD